GW Receives $2 Million for Phase 1 Clinical Trial to Test Hookworm Vaccines in Endemic Area

GW researchers are one step closer to fully protecting those most vulnerable from hookworm
May 24, 2016

MITM Researchers, Jeffrey Bethony, Ph.D. and David Diemert, M.D., received a $2.1 million U01 grant from the National Institutes of Health (NIH) to begin work on a Phase 1 clinical trial to test a hookworm vaccine in an endemic area of Brazil. This is the latest in a series of tropical vaccines being created and tested at GW.

“Tropical vaccines are getting a boost at GW,” said Bethony, the co-principal investigator (PI) on this clinical trial who is leading immunology efforts and is a professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences. “We have the capacity to do vaccine clinical trials here and in developing countries. It’s what we’re good at. Besides malaria, there isn’t another group that does this for tropical diseases.”

This clinical trial will be the first time immune interference has been tested using new antibody profiling methods and B-cell immunology.

Click here to read the full article.